BioSpace News Archive

Tremeau Pharmaceuticals to Host Key Opinion Leader Webinar on Rofecoxib in Migraine Management on Tuesday, October 25th.

PharmaEssentia USA Corporation announced the recent appointment of three new female executives to the company’s U.S. leadership team.

Venatorx Pharmaceuticals today will present new data during IDWeek 2022 for its novel investigational antibiotic cefepime-taniborbactam.

Revance Therapeutics, Inc. today announced that it has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for DAXXIFY™ for the treatment of cervical dystonia.

Bausch Health Companies Inc. today announced the presentation of eleven posters during the Fall Clinical Dermatology Conference, which takes place Oct. 20-23, 2022 in Las Vegas, Nev.

On a recently updated FDA list of artificial intelligence (AI) enabled medical devices, GE Healthcare had the highest number of authorizations, with 42 listed 510(k) clearances to date, in the United States.

Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that third quarter 2022 financial results will be released on Thursday, November 3, 2022 after the market closes.

Spark Biomedical, a leading developer of wearable neurostimulation solutions, has partnered with AcuityMD, a commercial platform for medical technology companies, to accelerate Spark Biomedical’s expansion of a new and growing market for treatment of withdrawal associated with opioid use disorder.

Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with members of Amarin’s senior management team to discuss the Company’s third quarter 2022 financial results on Thursday, October 27th, 2022 at 8:00 a.m. ET.

Excision BioTherapeutics, Inc., a clinical-stage biotechnology company developing CRISPR-based therapies intended to cure viral infectious diseases, today announced it will host a clinical expert webinar on HIV and the ongoing Phase 1/2 trial evaluating the Company’s CRISPR-based therapy EBT-101 as a potential cure for the disease.